ORTHO-CEPT
LOE ApproachingNDAORAL-28TABLET
Approved
Dec 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO-CEPT is an oral contraceptive tablet approved in 1992 by Johnson & Johnson. The product indication and mechanism of action are not specified in available data, but oral contraceptives typically prevent ovulation through hormonal inhibition. It is formulated as a 28-day oral tablet regimen.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), suggesting defensive positioning and possible team consolidation or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ORTHO-CEPT offers limited new job creation (0 linked positions), reflecting its mature stage and approaching LOE. Career moves on this product are typically defensive—managing market share decline, generic transition, and cost optimization rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on ORTHO-CEPT at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.